Loading...

We've got a brand new version of Simply Wall St! Try it out

UBI Pharma

GTSM:6562
Snowflake Description

Overvalued with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6562
GTSM
NT$883M
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The last earnings update was 87 days ago. More info.


Add to Portfolio Compare Print
  • UBI Pharma has significant price volatility in the past 3 months.
6562 Share Price and Events
7 Day Returns
-4%
GTSM:6562
-0.5%
TW Biotechs
1.7%
TW Market
1 Year Returns
-47.6%
GTSM:6562
-9.7%
TW Biotechs
18%
TW Market
6562 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
UBI Pharma (6562) -4% -47.7% -53.8% -47.6% -78.6% -
TW Biotechs -0.5% -2.7% -5.8% -9.7% -40% -41.5%
TW Market 1.7% 6.3% 9.8% 18% 27.8% 28%
1 Year Return vs Industry and Market
  • 6562 underperformed the Biotechs industry which returned -9.7% over the past year.
  • 6562 underperformed the Market in Taiwan, Province of China which returned 18% over the past year.
Price Volatility
6562
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for UBI Pharma's competitors could be found in our database.

Value

 Is UBI Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for UBI Pharma. This is due to cash flow or dividend data being unavailable. The share price is NT$6.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for UBI Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are UBI Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6562 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$-1.71
GTSM:6562 Share Price ** GTSM (2019-11-07) in TWD NT$6.2
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,434 Publicly-Listed Companies 16.64x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of UBI Pharma.

GTSM:6562 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6562 Share Price ÷ EPS (both in TWD)

= 6.2 ÷ -1.71

-3.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UBI Pharma is loss making, we can't compare its value to the TW Biotechs industry average.
  • UBI Pharma is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does UBI Pharma's expected growth come at a high price?
Raw Data
GTSM:6562 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.59x
Taiwan, Province of China Market PEG Ratio Median Figure of 241 Publicly-Listed Companies 1.11x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for UBI Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on UBI Pharma's assets?
Raw Data
GTSM:6562 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$4.45
GTSM:6562 Share Price * GTSM (2019-11-07) in TWD NT$6.2
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.43x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:6562 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6562 Share Price ÷ Book Value per Share (both in TWD)

= 6.2 ÷ 4.45

1.39x

* Primary Listing of UBI Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UBI Pharma is good value based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess UBI Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. UBI Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is UBI Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as UBI Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
61.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is UBI Pharma expected to grow at an attractive rate?
  • Unable to compare UBI Pharma's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare UBI Pharma's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare UBI Pharma's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:6562 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 61.6%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 58.8%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 10.8%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6562 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6562 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 438 -330 -242
2019-03-31 431 -281 -241
2018-12-31 424 -232 -241
2018-09-30 412 -192 -213
2018-06-30 400 -152 -185
2018-03-31 366 -153 -176
2017-12-31 333 -153 -167
2017-09-30 335 -75 -204
2017-06-30 337 4 -241
2017-03-31 347 21 -233
2016-12-31 358 39 -226
2016-09-30 389 -17 -135

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if UBI Pharma is high growth as no earnings estimate data is available.
  • Unable to determine if UBI Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6562 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from UBI Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6562 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 -1.71
2019-03-31 -1.71
2018-12-31 -1.70
2018-09-30 -1.51
2018-06-30 -1.31
2018-03-31 -1.24
2017-12-31 -1.18
2017-09-30 -1.44
2017-06-30 -1.70
2017-03-31 -1.65
2016-12-31 -1.60
2016-09-30 -0.95

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if UBI Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. UBI Pharma's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess UBI Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
UBI Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has UBI Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare UBI Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • UBI Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare UBI Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare UBI Pharma's 1-year growth to the TW Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
UBI Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from UBI Pharma Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6562 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 438.07 -241.72 124.44 228.06
2019-03-31 430.97 -241.34 107.44 238.87
2018-12-31 423.86 -240.97 90.44 249.69
2018-09-30 412.00 -212.86 81.47 220.27
2018-06-30 400.13 -184.75 72.51 190.85
2018-03-31 366.49 -175.96 65.95 179.28
2017-12-31 332.84 -167.17 59.39 167.71
2017-09-30 334.94 -203.98 55.00 205.98
2017-06-30 337.04 -240.79 50.61 244.25
2017-03-31 347.39 -233.26 51.92 242.68
2016-12-31 357.74 -225.72 53.24 241.11
2016-09-30 389.15 -134.53 53.91 187.45
2016-06-30 420.55 -43.34 54.57 133.78
2016-03-31 416.82 -20.64 54.40 105.79
2015-12-31 413.09 2.06 54.23 77.80
2014-12-31 409.04 38.60 41.56 28.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if UBI Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if UBI Pharma has efficiently used its assets last year compared to the TW Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if UBI Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess UBI Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
UBI Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is UBI Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up UBI Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • UBI Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • UBI Pharma's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of UBI Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from UBI Pharma Company Filings, last reported 4 months ago.

GTSM:6562 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 656.26 1,312.34 77.93
2019-03-31 656.26 1,312.34 77.93
2018-12-31 719.78 655.68 176.18
2018-09-30 719.78 655.68 176.18
2018-06-30 847.80 644.25 626.23
2018-03-31 847.80 644.25 626.23
2017-12-31 951.86 312.50 472.08
2017-09-30 951.86 312.50 472.08
2017-06-30 1,075.08 280.00 552.85
2017-03-31 1,075.08 280.00 552.85
2016-12-31 1,178.19 280.00 685.61
2016-09-30 1,178.19 280.00 685.61
2016-06-30 1,238.88 0.00 537.83
2016-03-31 1,238.88 0.00 537.83
2015-12-31 1,414.04 0.00 603.29
2014-12-31 545.80 0.00 58.57
  • UBI Pharma's level of debt (200%) compared to net worth is high (greater than 40%).
  • Unable to establish if UBI Pharma's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • UBI Pharma has less than a year of cash runway based on current free cash flow.
  • UBI Pharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 75.6% each year.
X
Financial health checks
We assess UBI Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. UBI Pharma has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is UBI Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from UBI Pharma dividends.
If you bought NT$2,000 of UBI Pharma shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate UBI Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate UBI Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6562 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1340 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6562 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2017-08-11 0.000 0.000
2017-08-10 0.000 0.000
2017-05-02 0.000 0.000
2016-08-12 0.020 0.076
2016-04-29 0.020 0.070
2016-04-28 0.020 0.070

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as UBI Pharma has not reported any payouts.
  • Unable to verify if UBI Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of UBI Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as UBI Pharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess UBI Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can UBI Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. UBI Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of UBI Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yong Chao Lin
CEO Bio

Dr. Yong Chao Lin serves as the General Manager and Director at UBI Pharma Inc.

CEO Compensation
  • Insufficient data for Yong Chao to compare compensation growth.
  • Insufficient data for Yong Chao to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team Tenure

Average tenure of the UBI Pharma management team in years:

4.5
Average Tenure
  • The tenure for the UBI Pharma management team is about average.
Management Team

Yong Chao Lin

TITLE
General Manager and Director

Meng Han Xu

TITLE
Manager of the Finance Department
TENURE
3.6 yrs

Jia Wei Hong

TITLE
Manager of Accounting Department

Yan Guo

TITLE
Vice President of the Business Development & Technological Service Center

Ying Yun Fan

TITLE
Head of Administration Office
TENURE
4.7 yrs

Bai Feng Wu

TITLE
Senior Vice President of Pharmaceutical Manufacturing Management Center
TENURE
4.7 yrs

Qi Hua Song

TITLE
Head of the Quality Assurance & Norms Office and Deputy Plant Manager
TENURE
4.3 yrs

James Peng

TITLE
Vice President of the Research and Development Center

Ming Yi Ba

TITLE
Deputy Head of the Engineering Office
Board of Directors

Chang Wang

TITLE
Chairman of the Board of Directors
AGE
68

Yong Chao Lin

TITLE
General Manager and Director

Jing Xu

TITLE
Vice Chairman of the Board of Directors

Xiu Lian Zhang

TITLE
Independent Director

Rui Wang

TITLE
Director

Su Qing Lin

TITLE
Director

Jiong Lang Liu

TITLE
Director

Ling Hui Zhang

TITLE
Independent Director

Xie Juan

TITLE
Member of the Supervisory Committee

Qing He Zhang

TITLE
Member of the Supervisory Committee
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess UBI Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. UBI Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and injectables. Its product portfolio includes film coated tablets, Virapine tablets, and Levetir concentrate solution for infusion. The company was founded in 2014 and is based in Hsinchu County, Taiwan.

Details
Name: UBI Pharma Inc.
6562
Exchange: GTSM
Founded: 2014
NT$882,836,941
142,393,055
Website: http://www.ubi-pharma.com
Address: UBI Pharma Inc.
No.45, Guangfu North Road,
Hukou Township,
Hsinchu County,
30351,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6562 Ordinary Shares Taipei Exchange TW TWD 22. Jan 2016
Number of employees
Current staff
Staff numbers
259
UBI Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/09 15:05
End of day share price update: 2019/11/07 00:00
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.